In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Value of E-Commerce

Executive Summary

For much of the past year, the promise of Internet-enabled e-commerce to deliver savings seemed just that: a promise. But a new study from Novation and Arthur Anderson goes a long way to finally putting some figures on the value and potential cost savings of a web-based supply chain.

You may also be interested in...



For Novation's Orthopedics Suppliers, The Internet as Mediator

For a variety of reasons, product companies have responded to the B2B supply chain phenomenon with reserve, wary of high transaction fees and little real benefit. B2B companies, in turn, have teamed up with leading hospital groups to overcome such resistance. But such a strategy only works where suppliers place a high value on GPO contracting. Where group contracting isn't well established, the approach works less well because there's no pull-through for the Internet program. But one group, Novation Inc., is in the early stages of an Internet program that would begin with one of the most challenging of group contracting markets: orthopedic suppliers.

Novation's E-Commerce Play

One of the last of the major hospital groups to commit to an Internet strategy, Novation has leaped into e-commerce with both feet through its recent deal with Neoforma. The company faces a host of challenges, not the least of which come from uncertain hospitals and reluctant product companies. For suppliers, the alliance of leading groups and dot-com companies raises questions about the future of the hospital marketplace.

Investors Go Beserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel